Cooperative Agreement U01CA296350
Award Date
5/1/25
Completion Date
4/30/30
Dollars Obligated
$486K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Cooperative Agreement
Place of Performance
Worcester, MA 01655, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $211,918 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the University of Massachusetts Medical School (UMass Medical) to develop next-generation proteomics technologies for transforming kinome research. The key products and services to be delivered include: Developing a targeted kinome assay to enable simultaneous absolute and relative quantification of the full human kinome (Aim 1). Developing a high-throughput...
This $720,252 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will support a research project led by the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The project aims to identify genetic variants that confer risk of common cancers, particularly prostate cancer, across diverse ancestral populations. The key products and services to be delivered include: Profiling regulatory element...
The National Cancer Institute (NCI) awarded a $225,101 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant will fund research to investigate the mechanisms underlying the increased risk of hematological malignancy (HM) in patients with sickle cell disease, including those who have undergone gene therapy or hematopoietic stem cell transplant. The research aims to determine if oxidative stress-induced DNA damage in...
The National Cancer Institute (NCI) awarded a $158,020 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The grant, awarded on August 18, 2025, supports research to investigate the role of mutagenic DNA repair pathways, such as microhomology-mediated end joining (MMEJ), in driving acquired drug resistance in persister cancer cells. Specifically, the project aims to (1) study persistence mechanisms in BRCA1/2-mutant cancer...
The National Cancer Institute (NCI) awarded a $101,948 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Van Andel Research Institute (VAI) in Grand Rapids, Michigan. The grant aims to characterize germline variants and perform functional validation of variants in a zebrafish model of high-risk pediatric acute myeloid leukemia (AML). During the subsequent K00 phase, the project will focus on examining germline regulatory, splicing, structural variants, and...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research (CFDA 93.393) program, will support the development of an Integrative Analysis and Visualization Platform for Cancer Regulatory Genomics. The $416,745 award to the University of Massachusetts Medical School (UMass Medical) aims to create a comprehensive atlas that connects regulatory genomic elements to cancer-associated genes. The project will also perform in-depth...
The National Cancer Institute (NCI) has awarded a $1,062,474 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Massachusetts Institute of Technology (MIT) for a five-year research project titled "IMPACT OF DNA REPAIR PATHWAY INTERACTIONS ON THE MOLECULAR AND PHYSIOLOGICAL CONSEQUENCES OF METHYLATION DAMAGE". The project aims to study the biological consequences of DNA damage caused by the carcinogenic agent N-nitrosodimethylamine (NDMA) and the...
This Project Grant award of $344,111 from the National Cancer Institute under the Cancer Biology Research (CFDA 93.396) program will support research by Loyola University of Chicago's Health Sciences Campus to investigate targeting panoptotic pathways for the treatment of myelodysplastic syndromes (MDS). The project aims to determine if genetic inactivation or pharmacological inhibition of RIPK1 and TBK1 can prevent MDS development and eliminate mutant hematopoietic stem/progenitor cells,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $601,169 to the University of Virginia from January 2025 through November 2028. The research aims to better understand the molecular mechanisms underlying the progression of myeloproliferative neoplasms (MPNs), a group of blood cancers, with a focus on the role of the PTPN1 gene and TIMP-1 protein in enhancing the effects of the...
This $1,290,499 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports a research project led by the Dana-Farber Cancer Institute, Inc. (Dfci) in Boston, MA. The project is studying the effect of clonal hematopoiesis on cardiovascular-related outcomes in patients diagnosed with kidney cancer. The four-year research effort, which commenced on September 1, 2023 and is scheduled for completion by August 31, 2027, aims to advance...